PCM
LYEL icon

Prelude Capital Management’s Lyell Immunopharma LYEL Stock Holding History

Prelude Capital Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,265
Closed -$56.4K – 1377
2024
Q1 		$56.4K Buy
1,265
+390
+45% +$16.7K ﹤0.01% 1249
2023
Q4 		$34K Buy
+875
New +$31.5K ﹤0.01% 1085
2023
Q3 		– Sell
-638
Closed -$40.6K – 1262
2023
Q2 		$40.6K Sell
638
-912
-59% -$50.5K ﹤0.01% 985
2023
Q1 		$73.2K Buy
+1,550
New +$82.9K ﹤0.01% 980

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prelude Capital Management's LYEL Position: Q2 2024 in Review

Prelude Capital Management sold out of Lyell Immunopharma (LYEL) in Q2 2024, closing a stake of 1,265 shares — an estimated $56.4K sold.

Prelude Capital Management first reported a position in LYEL in Q1 2023 and held it in 4 quarters. The position peaked at $73.2K in Q1 2023. 120 funds tracked by Wall St. Rank hold LYEL as of Q2 2024.

  • Prelude Capital Management reported no remaining Lyell Immunopharma position as of Q2 2024 after selling out during the quarter.
  • Prelude Capital Management sold 1,265 Lyell Immunopharma shares in Q2 2024, an estimated $56.4K.
  • Prelude Capital Management first reported a position in Lyell Immunopharma in Q1 2023 and held it in 4 quarters.
  • Prelude Capital Management's Lyell Immunopharma position peaked at $73.2K in Q1 2023.
  • 120 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2024.

Based on Prelude Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.